get set..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VITX called in live chat
if i don't pat myself on back noone else will either...LOL
(10:27 AM) pumperbasher: Out TWTC....thanks moving
mcmike: TWTCmay not be done...good call for sure...i'm in VEXP looking to bust into the mid 10s
mcmike: another R/S potential runner is VITX...very nice volume bursts to day..at hod and over 1x avg daily vol
mcmike: moving as i write
(10:57 AM) movingup: til eod
mcmike: VITX hod
mcmike: VITX up .25 from vol alert....
(11:03 AM) movingup: nice alert earlier
mcmike: VITX wowie
mcmike: leaving VEXP in the dust
VEXP R/S runner; shorts getting squeezed all over
ANTP
HLIT
Scan Hits for Mon 6/6/05 too late for me to paste charts in
Oversold: BRKT IMNR CLTK LINK ECGI LGBT
Upside Resumptions: MXC FUEL NGPS TZIX STTS
60 Bullish Engulgs: IBIS ONT ANTP NYER BRKT TEN
Breakout candidates: CMT AQNT AMHC LRW CZR
LateInterestHiVolHiBOP: FLEX NMGC OTD
CPTH flagpole & flag
haven't polished my crystal ball, but stocks that nearly double in less than 2 business days sometimes have a bit of digesting of gains to do.
did not look at Thompson for instit. activity over last week. you might want to do so.
Looking at a 1 minute chart of today's activity and at block trades of 30K shares or more I see
6 green
4 yellows
2 reds
I think quotetracker goes by uptick same tick downtic for the colors.
Better no long top wick than a big one, but better a white candle than a red. I think CPTH is headed higher, but if you are looking for a trade,not a swing or an investment for a couple of weeks you might want to look elsewhere.
CPTH needs a close above .70 before it can surpass the 200dy SMA in the .85 area
just my guess
wow doesn't begin to describe CPTH...unreal!
Charts of note: CPTH DENN TUTS VITA GEMS
CPTH 52 wk low: reversal off bottom
DENN bullish engulfing candles
TUTS short term stochastics turn up; xing 200dySMA; going green on the TC2000 BOP indicator (balance of power)
VITA breaking yearlong downtrend line on nice volume
GEMS strong stock keeps on keeping on
RCO Ch.11
guess i was right per my previous post
http://www.investorshub.com/boards/read_msg.asp?message_id=6459194&txt2find=rco+
sometimes DD can save your behind.
my condolences to the hopeful who remained long.
I would not be surprised to see a PBM (pharm.benefits manager) come in and swoop up the intellectual property for, let's say .25-0.30 on the dollar.
have never done any patent exploration on the co. i wonder if their software is protected in any way.
scheduled to speak with Dave Kittrell, Xpention president
I have been trading voicemail for a couple of days.
If you have any questions you would like me to ask of him pls pm me.
will be calling him back midday Sunday.
good weekend all
OTC FN "Special Situations Report" on XPNG is in the mail
Spoke today with the publisher Geoff Eiten:
800,000 "Superstock Investor" mailers went out late last week under a different publisher (we have seen the scans from Olico's folk :) ). Geoff was quite aware of the first mailer.
1 million SSRs left the printers yesterday and today.
These advertisements travel by snail mail at the cheapest postage rates and can take a week or more to reach mailboxes. i believe he stated that the printer was located in St. Louis so that the Midwest should get them first.
Geoff expects that "the run" will progress over the course of about 3 weeks.
He referred me back to theRegencyGroup if I had questions about who paid for these promotions.
He told me that the bad number in the pdf mockup file that was linked via the email a week ago had been corrected (before I found it to be bad, though that is not the impression I got from Rick M. in the same shop!) and that it was more like a rough draft. He did not know how it had gotten linked on the web, but stated that, as long as it leads to subscriptions for the OTC Growth Stock Watch the free advertising for him was no problem.
.....
XPNG sellers worked through SCHB this week. The most telling day was Wednesday when a great deal of buying came in at the 1.15-1.16 area and SCHB could not be moved off of the ask. Omnitrader in the live chat stated that it was not unusual to produce a shake before a promo.
There are a couple of less well known market makers that can clue you into bid support imo:
BGTN, Brockington whose area code ID is Long Island, NY
PENA PENNALUNA & COMPANY, COEUR D'ALENE ID
I am encouraged by the late action. good luck to all
PAY was better...
bought at the open and had to take 16.35 way beyond my expectations for the day.
stock moved 1.50 on the CNBC interview in 10'
this was a coming out party imo.
is still so close to the IPO that no investment houses have put out recommendations
conf call was enlightening.
will look to add back in 14 area hopefully.
super VRA call
ANX redux: bullish morning star + FNSR TBUS BRCD
http://www.investorshub.com/boards/read_msg.asp?message_id=6557854
Chart Scans: ANX FNSR TBUS BRCD
ANX 2.45 bullish morning start config.
ANX: EKN Securities Starts @ Outperform; Sets Tgt @ $9
http://www.knobias.com/individual/public/news.htm?eid=3.1.1b37f850ce717ae1bc64d50ab61327ccc97e6c26dc....
FNSR bullish engulf
TBUS continuing reversal from 52wk low
BRCD upside bounce from 52 wk low
Due Diligence #5 (see end of post for my response 3dcg)
I spent a couple of hours on the phone today with
J. Pollack http://palmbeachpr.com/index.shtml
Brian Cook from theRegencyGroup
& Murray Fleming, XPNG IR. check the ihub box
..........
and who DID provide Agile Investments with the bad telephone number? I still don't know who that non-affiliated third party is.
Neither does Jason, Brian or Murray nor do any of these pretty knowledgeable persons have any ideas who is behind the large promotions "Superstock Investor" or the imminent?! OTC FN "Special Situations Report"
.........
What I did learn today is that J. Pollack & theRegencyGroup have a broad list of investment professionals that they contact on a periodic basis and that emails about XPNG have gone out to them.
The inside group, at least those who were part of the original Bayview Mgmt LLC which purchased the shell for XPNG are not looking for a short term trade. If one or some of them are organizing the promos, none of the folks I spoke with know anything about it.
....
Murray told me that the investor package has an 8 pager that describes in some detail the
I have heard people put down the idea of the play because it is a biotech startup and it takes years to see a return. The differences in this play are:
1. the company has a revenue-generating plan for the near term via the veterinary business plan that will ameliorate the common repetitive & dilutive money raising routines that many startups have to go through.
2. the qualitative and quantitative measure of the cancer marker make the diagnostive testing aspect a price-reasonable target goal that does NOT require FDA trials or approval. It will require relationships with a CLIA-certified lab.
If they should be so lucky as to get to the point of trying to develop a vaccine, which would need the FDA approval gauntlet, most traders will be long gone...
Anyone interested should at least read Section 8.01 Other events from the 3/18/05 8K12G3 that i referenced before. Here is the link again:
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001072588%2D05%2D000047%2Etxt&FilePath....
The text is nearly identical to the 3 pager that Brian from the RegencyGroup sent me last Friday.
Still looking at Level II for the bid support before completing my position.
p.s. I asked almost everyone I spoke with today about the double-edged scenario: either the promotion and markup phase has yet to start, or 2. the accumulation and positioning was done very early in the .80-1.00 range and the promo will be a buy the rumor sell the news scenario for the monied interests that paid for the promos, and they have no intent to support the bid as was done in the LLLI case.
Noone had any answer. They really don't know who is behind the promo. Brian found it VERY unusual that SCHB has been selling consistently and capping the share price. He did not have much regard for momentum traders who just wanted to scalp. He did understand why LLLI piqued our interests and what bid support means to a successful promo. Aaron knows this as well.
I have done about all I can on this... burned all my cell minutes and more (ugh!). Will keep watching the level II box and sharing anything more that comes my way.
..........
How much should I ask of the promoters of the OTC FN "Special Situations Report" for catching the IR telephone error before the mailer went out? 800K glossies and postage all worthless? Hmmmm...
Vancouver Sun expose of LLLI link
http://www.investorshub.com/boards/read_msg.asp?message_id=6546322&txt2find=vancouver+
The article is somewhat off the mark re. Higgs imo:
"In conjunction with the merger, the company privately sold 1.5 million units for $1 US each to a company called Higgs Investment Group Inc., domiciled in the Turks and Caicos, a tax and secrecy haven popular with Canadian promoters. Each unit consists of one share and warrants to buy two more shares at $1.25 to $1.40 US each, for a total of 4.5 million shares.
The beneficial owner of Higgs Investments is not revealed in the company’s filings, but the ever-helpful Lampered said “that’s the company he [Jordan] is involved with.”"
The 1.5 million was started with a bridge loan to assist in the corporat reorganization. It was completed via a private placement done under Reg S. It is well documented in the filings.
If Higgs sold their stake or exercised their warrants and sold them without a registration statement then you might have something to knaw on, imo.
As I have stated elsewhere, Higgs or their proxies made a lot of money for a lot of traders by supporting the bid over an extended period of time AND paying over 1.3 million to do the Eiten OTC Spec. Sit. report that brought a lot of attention to the stock.
I saw no evidence that the company sponsored the promotion with Higgs $. That would be malfeasance.
Bad mouthing a promo that worked without discussing how it worked seems crass to me.
Daily trading notes: QUIK CPST SFP ANTP XPNG PAY EZTO
took 1/2 off on QUIK for redeployment...not clear anymore that the breakout IS coming..couldn't get to yesterday's hod and just not that liquid
CPST mentioned as bottom reversal in live chat. Had a "green" candle in TC2000... meaning that the proprietary Balance of Power Indicator is favorable. Last green candle in March in 1.60 area
SFP mentioned as a wowsa. Very squeezeable. you can check the key stats for yourself if you are inclined: http://finance.yahoo.com/q/ks?s=sfp
ANTP was stellar yesterday. not sure who is in control at present as i took a nice gain too early when I wasn't going to be able to monitor it closely.
XPNG what a time/energy sink. My belief is that the monied interests paying for at least 2 glossy mailers got preempted by an email promo costing about 80K a week ago, and they are not on the bid yet (they want the cheaper shares). The Vancouver Sun did an expose, mostly factual, hatcheting LLLI, the best stock promotion I have witnessed since joining ihub.
Geoff Eiten's Special Situtions Report on LLLI has been the highest generator of subscription revenue for them, or so I was informed, and the SSR for XPNG is due for distribution imminently. If some of the LLLI gains rotates to the next OTC FN glossy it will be something to behold.
btw, the OTC FN has been HOT HOT HOT, to wit: LLLI ad, InvRelations for BRVO, AVVW, and as of yesterday AOOR (which i find completely unworthy of my $). This was great coup for AOOR to have OTC FN pick them up as a client and for only 100K shares if I remember. I could go on a rant after looking over AOOR financials...but i won't bore you. I'll just say that a dilutive financing is due and it should be a doozy.
If you check one of my previous posts
http://www.investorshub.com/boards/read_msg.asp?Message_id=6379524&txt2find=pay
you will find that I have been interested in PAY. Verifone had their conference call this afternoon. I am sorry I waited to buy shares until the earnings report. The stock is up $1.00 in AH trading on evidently excellent earnings.
When the quiet period ends PAY is going to pay imo, and it is already paying...
Another "trade" that has turned in to an investment is EZTO. They had potentially postitive news today, but the stock did not catch fire:
EZ2 Companies, Inc. Launches E2Stream.com, Enabling Online Video Recording for Online Auctions
http://www.knobias.com/individual/public/news.htm?eid=3.1.e942dd7fbded2c30ba52d832356eb2f48b0bc35d59....
Disclaimer: after 6 months of trying to trade OTC/bb stocks I can safely let all know that they should pay no attention to what I say about any of them... I have no clue. Pure crap can soar...and quality stories go nowhere, with no rime or rheason (sic). Learning how to read the promotion cycle is everything, fundamentals almost nothing....except CAMY
BWNG 5.45 R/S runner 1:10 in October; volume building
possible assault to the 200dy MA?
looks like a little bit of price/volume acceleration
"the real promo"
who knows...really
If by "real promo" you mean that a duplication of the run seen by LLLI's promoters...certainly not.
If you mean that maybe Eiten's ad will have lightning in a bottle 2x maybe yes.
the big Q 9 (for me, anyway) has always been: who is behind all the high buck promotional expenses and will they represent strength in the stock through one or more market makers absorbing all sells and spending more money to start the run by whacking the ask.
thx Olico
what I was hoping to hear was WHO is paying for all of these promos.
Agile Investments was the recipient of the $80K for the email that went out last Friday
CFM received $600K for the "Superstock Investor" glossy, and C.I. Marketing received $560K for the yet to be seen Eiten "Special Situations Report" that we were able to see the pdf file of.
It doesn't sound like you were able to get the name of the payer of the $600K.
...
I have calls in to both the XPNG CEO and Murray Fleming, the IR contact from Catalyst Investor Relations.
Don't know if this has been posted before. This is from the disclaimer of the soon to be mailed out Eiten SSR (i heard after the close from someone who spoke to OTC FN that the distribution date for the first printing is supposed to be Friday):
CIM, as well as various affiliated companies
and vendors have received and managed a total production
budget of five hundred sixty thousand dollars received from
0711005BC, Ltd. (LTD) for this advertising effort and will retain,
over and above the cost of production and publication, any
amounts that remain as additional compensation for production
services relating to the advertising and publishing efforts.
Please make special note that LTD owns shares of XPNG and
reserves the right to sell any or all of its shares in any company profiled at any time, be that before the date of a profile, during the date of a profile, or at anytime after the date of a profile, as has been the practice of XPNG on many occasions. OTC expects to receive new subscriber revenue, the amount of which is unknown at this time.
I will continue to try to identify the money source for the promotions to determine what kind of bid support we can expect, and maybe more importantly....WHEN!!
Due diligence #4 Company IR # IS 888-359-9505
Spoke with Aaron Lamkin of the Regency Group and Rick from OTC FN today.
I sent both copies of the email promo I received late last week with the link to the portal that had the pdf of the upcoming Eiten "Special Situations Report"
The bad telephone number was evidently a paste from a bad phone number for the company's IR that was published on 4/27.
Murry Fleming of Catalyst Investor Relations is the IR person, but the teleph # in this release belongs to another investment firm that has nothing to do with XPNG
http://www.knobias.com/individual/public/news.htm?eid=3.1.edb7d553eb71cce89919cded44bb9134ed659eba23...
don't call that number
When I called the right number on friday i reached Barry Reagh who sent me a great 3 pager that utilizes a lot of the same language as that of the website, but very well organized.
Eiten referred me to the RegencyGroup which confirmed for him some of the details of the advertisement that they now have at the printers.
The Regency group is not doing the promo. The group that purchased the shell have 144 stock. They have no idea who has paid for the promos.
I have left a message for Mr. Kittrell (KIT trel).
Regency will be assisting XPNG in lining up the 3-5 million later in the year when the company needs working capital for the second phase of their plan. They are hoping it will be with a fund in an equity deal, and hopefully with restricted shares.
They are not directly responsible for helping XPNG with the first raise, though there have been a number of offers.
.............
Rick from the OTC FN confirmed that their mailing has not yet gone out.
It is the marketing group that chooses the size of the distribution. LLLI report was due to go to 2.8 million households. they did the first half, but never had to pay for printing and postage on the 2nd half because it took off! Wow!
These advertisements go out in tranches to build momentum and don't all get into target mailboxes at the same time.
Olico will try to find out who paid for the "Superstock Investor" promotion.
It is truly a mystery to me why people who are spending significant dollars are not supporting the stock today.
My personal belief is that someone let the word get out via email before the mailer promoter types got to fill their coffers with shares and now the mailer type supporters are shorting to get cheap shares before their promos hit.
sort of a mess...too many promoters stepping on each other is my guess.
GOAM & BWNG R/S runner candidates with potential
GOAM
BWNG
Was a little late on ERHE due to tieup on XPNG due diligence but am in. I don't think people realize what a win this was for such a small company.
Ken, check out this chart:
FUEL
you can see from the top indicator why i am so attached to the short term stochastics
Supercharts!! FUEL INNO NTMD JLG
FUEL
INNO oversold bounce candidate
NTMD 36%of free float after substracting institutional ownership is short
JLG all time high breakout...i know nothing about co. except i think they make mobile telescoping work platforms
re. Eiten and stock promotion...for dc 320 & bocxman...imo
The umbrella organization for Geoffrey Eiten is National Financial Communications
http://nfnonline.com/gjeiten.html
National Financial Network is a division of National Financial Communications
http://www.otcfn.com/
OTC Financial Network, a division of National Financial Communications Corp., is a full-service financial communications and investor relations firm that specializes in emerging, micro/small-cap companies.
http://www.otcgsw.com/
OTC Growth Stock Watch reports on companies with a market capitalization under $100 million dollars, which meet a set of Publisher and Chief Analyst Geoffrey Eiten’s rigid performance criteria: minimum 2-to-1 current ratio, minimal or no long-term debt, niche-oriented products and services, and an annual growth rate of over 20%.
I cannot speak to the BSTOR story, but if you look at the otcfn website you will see they have IR services including IR Services... Short and Long-term Consulting; Web-enabled CEO Reports on Audio and Corporate Streaming Videos; Email Blasts; Live and Archived Conference Calls; Investor Facts Reports.
Companies pay NFN for IR services. They do not shamelessly promote bad companies, but companies can fail. I know they worked with CLN...probably long before the FDA approval and the stock selloff..
As regards the OTC Growth Stock Watch...this is a long running monthly newsletter that updates subscribers about companies in the portfolio, why companies are deleted, and news blurbs about companies in the portfolio, and a featured new company each month for addition to the portfolio. I was sent the most recent issue after the LLLI promotion after speaking with Geoff. I am not a subscriber.
The OTC FN reviews lots of companies for publication of "Special Situations Report". Eiten does review the copy before publication. The purpose of these reports is to highlight promising companies with a splash for the purpose of adding to his subscription base. These companies do not rate OTC Growth Stock recognition according to the above criteria.
hope this helps...The OTC FN has been around a long time.. They must be doing some things right, but I have no "proof"
Olico...
can you confirm from the disclaimer or other text that this is even a promo from Eiten and the OTC FN? It may be someone else's promo.
XPNG shares outstanding:
4/21/05 10Q
State the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 4,372,500 shares of $0.001 par value common stock outstanding as of April 14, 2005.
Wednesday, April 13, 2005 18:58 ET
Bayview Corporation Effects Name Change and Forward Split
http://www.knobias.com/individual/public/news.htm?eid=3.1.4d7c011e56057dd5c180952b2ca1ac0fb19da9d107....
Xpention Genetics Inc. (OTC BB: XPNG), formerly Bayview Corporation (OTC BB: BYVW), completes name change and thirteen for one forward split. The name change and stock split was effective Tuesday, April 12, 2005.
Obviously the company needed more shares outstanding to create a potentially liquid market.
Still, it's a bit of a faux pas, as I haven't found any filing that actually discusses the forward split.
Someone had an oversight evidently as the 4/18/05 8K acknowledges the name change.
In my first DD post
http://www.investorshub.com/boards/read_msg.asp?message_id=6505952&txt2find=reagh+
i posted the 1pager that Barry Reagh sent me from the IR listed in the email promo:
the current O/S is exactly 13x the 4.37 mill. O/S from the 10K
a true tragedy! Grolsch and not Miller or Bulb Lite!
I find it quite interesting Olico that
1. they list the price at 1.20
2. the headliner is neither OTC Growth Stock Watch nor Special Situations Report which was linked in that Friday email.
3. can you let us know the IR# that this promo has if you want more information?
I will speak with OTC FN tomorrow and get the lowdown on the different header.
Multiple promotions:
Knights Bridge Holdings has been responsible for a number of low budget mentions:
possibly the first promotions on the same day 4/28/05:
http://www.stockhouse.com/news/news.asp?newsid=2744676&tick=CIEN
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for newsletter and ad services for XPNG (Public Company). The compensation twelve hundred dollars from a non-affiliated third party, Knights Bridge Holdings Inc
http://www.apria.com/resources/1,2725,494-321838,00.html
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for newsletter and ad services for XPNG (Public Company). The compensation twelve hundred dollars from a non-affiliated third party, Knights Bridge Holdings Inc.
Knights Bridge Holdings also paid for 3 mentions through eLocity Inc on 5/3:
http://www.knobias.com/individual/public/news.htm?eid=3.1.dce358ddf165e2a84c524ebfb72846473539053eaa...
http://www.knobias.com/individual/public/news.htm?eid=3.1.5e9814b8714db4cf6a47a3498a3a94102f8455268f...
http://www.knobias.com/individual/public/news.htm?eid=3.1.90603910c8542514ac0916d6958b8c350204851c78...
at $1000 each.
the above bits caused no blips in price or volume that i saw.
the email from CCarver@investorsobserver.com
Although investorsobserver.com is for real...the email promo's mail address is a UPS Store mailbox with a link to "Your Daily Stock Tip" which my computer detects as spam: Spam detection software, running on the system "comedi.org", has identified this incoming email as possible spam. The original message has been attached to this so you can view it (if it isn't spam) or label similar future email.
The CCarver email had the link to
http://204.9.191.148/XPNG/index.htm which is
a QuoteMedia portal with a link to
http://204.9.191.148/XPNG/XPNG.pdf
the "galley" version of an OTC SS report that wasn't suppposed to be available online (sez Rick from OTC FN)
The Carver email was fairly slick and had a bigger budget: $80,000 as previously mentioned from an unidentified third party.
http://www.thelion.com/bin/forum.cgi?msg=780499&tf=wall_street_pit&cmd=read
"The Daily Profit Trader," from Knights Bridge Holdings, hyped Xpention Genetics, whose scientists, it said, "could be about to make history with the World's first Cancer Vaccine!" in exchange for $50,000. No source of the funds were disclosed.
I have never seen "The Daily Profit Trader"
I have no idea who Knights Bridge is
I am EXTREMELY CURIOUS how the group that spent $80K for the email that started my queries got hold of the link to the OTC FN copy and linked it when THAT promo cost $560K which flowed from:
0711005BC, Ltd (LTD) to C. I. Marketing which is a financial communications company.
I have, somewhat unfortunately, yet to find out who is behind all of this...
but am still on the hunt.
btw... I had to find a news release about the forward 13:1 split. don't have any filing though it seems like there should be one (may have missed it) http://www.knobias.com/individual/public/news.htm?eid=3.1.4d7c011e56057dd5c180952b2ca1ac0fb19da9d107...
My explorations today are like the strawberries I put on my cereal this morning...they were gorgeous when I bought 'em last week, but after forgetting about them over the holiday weekend...they don't look quite as appetizing
Due Diligence #4 DON'T CALL THAT NUMBER!
In the email that I received that started my interest in XPNG there was a line that said: Another ground breaking news alert from XPNG.
That link took you to a portal profile for XPNG from "Quotmedia"
There was a thumbnail image of a "OTC Growth Stock Watch" report for XPNG
That is where I found the OTC Special Situations Report.
I called the toll-free # and got an investment house that is NOT CONNECTED to XPNG in any way....
Don't call that number.
I called Rick M. at the OTC FN to find out what happened?
The "OTC Special Situations Report" for XPNG is still at the publishers and what was posted was evidently a galley proof-like copy and not the final.
I questioned the $1.50 stock price in that report last night. They evidently are going to plug a number in and were speculating that that might be the price when the issue is due to be mailed.
The email I received on XPNG evidently "leaked" the OTC Special Situations Report. Probably shouldn't have done that.
Make of this what you will.
Charts of interest: SCLN CRYP STXN ECIL XXIA TBUS TERN ODSY EMKR
SCLN: the end of lower lows and lower highs?
CRYP just went green on TC2000 balance of power & coming up from oversold. i have a broker friend who has liked this from 25 gap in February
STXN uptrend resumption
ECIL uptrend resumption
80 hits on the bullish engulfing scan!!! the best are those coming out of downtrends with nice volume:
XXIA
TBUS looks like there is a seller who might get taken out at some point...bears watching
TERN same as TBUS
ODSY 200day MA bounce play?
EMKR cup with handle breakout? CwH
XPNG 1.25 the next bb runner?
I told some fellow investors last Friday that I would undertake some due diligence over the weekend and have done so.
http://www.investorshub.com/boards/read_msg.asp?message_id=6505952
http://www.investorshub.com/boards/read_msg.asp?message_id=6510450
http://www.investorshub.com/boards/read_msg.asp?message_id=6518367
http://www.investorshub.com/boards/read_msg.asp?message_id=6518471
http://www.investorshub.com/boards/read_msg.asp?message_id=6518846
http://www.investorshub.com/boards/read_msg.asp?message_id=6519072
Traders are excited about this ticker due to the success of the recent LLLI promo which also began with an OTC Special Situations report published by Geoffrey Eiten.
That co., with nominal revenues, but a business plan to market less lethal weaponry, had a fantastic promotion.
XPNG came to the attention of the traders via the rumor mill in the middle of last week in the 1.20 range as the next "LLLI"
In point of fact, XPNG has more than one promoter behind it.
An email came out late Thursday highlighting Eiten involvement. It noted that the stock price was 1.16
The promotion had links, one of which is evidently a pdf file of the OTC Special Situations Report which has yet to hit the mailboxes of the OTC FN mailing list. The OTC SS report indicates the stock is trading at 1.50. It only had one tick there on the first day of trading which I assume was WELL before this mailer was put together....Is that where they are going to run it in the next few days????
You can be sure that when it does there will be some excitement. $80,000 was given to Agile Investments by "a non-affiliated third party" for the email promo. The OTC SS disclaimer states that: C.I. Marketing LLC managed it's publishing. "CIM, as well as various affiliated companies
and vendors have received and managed a total production
budget of five hundred sixty thousand dollars received from
0711005BC, Ltd. (LTD) for this advertising effort and will retain, over and above the cost of production and publication, any amounts that remain as additional compensation for production services relating to the advertising and publishing efforts."
Noone has yet identified C.I.M., the third party, or the 0711005BC, Ltd who are doing the promo.
Noone knows who is going to support the promotion by staying on the bid.
Higgs or their proxies did so for LLLI spectacularly, and one would assume that the 1.3 million they spent to promote LLLI out of their own pocket was recouped during the markup of LLLI.
Traders didn't get wind of this promo until the stock had moved on very light volume from the 1.20 area up to 1.90.
I don't think anyone is claiming that XPNG has reinvigorated cancer research and therapy. the fact of the matter is that the company's promotional materials are not full of hype. If they ARE successful in moving from immunological (qualitative) diagnostics to a licensable molecular assay test (quantitative) for the P65 marker they COULD provide a low-cost test to determine if a treatment regimen is effective (reducing the P65 "load" levels. I know nothing about RNAi technology or the possiblity that the company wants to develop a vaccine that will interefere with P65 expresion. I don't think anyone is expecting a miracle here.
Is this any less sexy than a molybdenum(?) projectile that doesn't kill people in extreme conditions like like rubber bullets? LLLI has no money either, but they do have a plan.
I have been told that there are a number of news releases coming for XPNG and the big one (watershed) will be that on the financing terms. The company's plans are not requiring vast amounts of dollars upfront (1-1.5 million). If this is a significant opportunity, then monied interests will sidle up to the trough with dollar offers that are not big-time dilutive, and will be willing to take kickers above the current share price levels.
It also seems like a plus to me that they have brought one of the orignal patent filers on board, and that they are running lean with just the two employees.
I took a starter position. Should be fun to watch particularly if the OTC Special Situations Report DOES start hitting people's mailboxes this week.
bocxperson:
I told some fellow investors last Friday that I would undertake some due diligence and have done so. Traders are excited about this ticker due to the success of the recent LLLI promo which also began with an OTC Special Situations report published by Geoffrey Eiten.
That co., with nominal revenues, but a business plan to market less lethal weaponry, had a fantastic promotion.
XPNG came to the attention of the traders via the rumor mill in the middle of last week in the 1.20 range as the next "LLLI"
In point of fact, XPNG has more than one promoter behind it.
An email came out late Thursday highlighting Eiten involvement.
The promotion had links, one of which is evidently a pdf file of the OTC Special Situations Report which has yet to hit the mailboxes of the OTC FN mailing list.
You can be sure that when it does there will be some excitement. $80,000 was given to Agile Investments by "a non-affiliated third party". The OTC SS disclaimer states that: C.I. Marketing LLC managed it's publishing. "CIM, as well as various affiliated companies
and vendors have received and managed a total production
budget of five hundred sixty thousand dollars received from
0711005BC, Ltd. (LTD) for this advertising effort and will retain, over and above the cost of production and publication, any amounts that remain as additional compensation for production services relating to the advertising and publishing efforts."
Noone has yet identified C.I.M., the third party, or the 0711005BC, Ltd who are doing the promo.
Noone knows who is going to support the promotion by staying on the bid.
Higgs or their proxies did so for LLLI spectacularly, and one would assume that the 1.3 million they spent to promote LLLI out of their own pocket was recouped during the markup of LLLI.
Traders didn't get wind of this promo until the stock had moved on very light volume from the 1.20 area up to 1.90.
I don't think anyone is claiming that XPNG has reinvigorated cancer research and therapy. the fact of the matter is that the company's promotional materials are not full of hype. If they ARE successful in moving from immunological (qualitative) diagnostics to a licensable molecular assay test (quantitative) for the P65 marker they COULD provide a low-cost test to determine if a treatment regimen is effective (reducing the P65 "load" levels. I know nothing about RNAi technology or the possiblity that the company wants to develop a vaccine that will interefere with P65 expresion. I don't think anyone is expecting a miracle here.
Is this any less sexy than a molybdenum(?) projectile that doesn't kill people in extreme conditions like like rubber bullets? LLLI has no money either, but they do have a plan.
I have been told that there are a number of news releases coming for XPNG and the big one (watershed) will be that on the financing terms. The company's plans are not requiring vast amounts of dollars upfront (1-1.5 million). If this is a significant opportunity, then monied interests will sidle up to the trough with dollar offers that are not big-time dilutive, and will be willing to take kickers above the current share price levels.
It also seems like a plus to me that they have brought one of the orignal patent filers on board, and that they are running lean with just the two employees.
Thanks for protecting us from ourselves. Goodbye?
XPNG Due Diligence #3
from the 1/19/05 8-K
The Xpention rollup
the Regency Group helped Mr. Kittrell assume control of the shell formerly known as Bayview Corp. It appears the Xpention's CEO and the Regency Group paid 725K to get 1.050 million shares of Bayview unde the new entity Bayview Management LLC. They received the right to replace the former Board
from the 1/24/05 SC 13D filing:
Aaron Lamkin, Manager and primary beneficial owner of Bayview Management, LLC. The primary beneficial owner is The Regency Group, Inc. which owns 50% of the LLC of which Mr. Lamkin is a principal and a director.
The Regency Group is a Management and Financial Consulting Company whose primary business is assisting private companies with day to day operations and transitioning into the public market. Mr. Lamkin has been involved in many mergers and acquisitions and continues to consult these companies on an ongoing basis.
from the 2/17/05 8K
the reverse merger?
Bayview acquires 100% of Xpention:
The Company has entered into a Definitive Agreement with Xpention (XPI) and its shareholder to acquire 100% of the issued and outstanding shares of Xpention.
The Shareholders of XPI shall exchange all of their shares of XPI (constituting at least 100% of the issued and outstanding common stock of XPI) for 1,100,000 common shares of Bayview common stock. The transactions contemplated by this Agreement shall be completed at a closing ("Closing").
The transaction is conditional upon delivery of audited financial statements of XPI prior to closing.
2/17 news: On February 17, 2005, the Company entered into a License and Technology Agreement with the University of Texas M.D. Anderson Cancer Center to commercialize technology developed for cancer detection in animals and humans.
from the 3/18/05 8-K12G3 THIS IS THE MEATY FILING FOR THOSE WANTING TO DO THE SERIOUS DUE DILIGENCE
D. Kittrell is issued 1.1 million shares in exchange for all the shares of Xpention resulting in Kittrell's ownership of 25.16% of Bayview
This filings describes all of the patents that have been issued as well as their plan of operation as well as the PATENT AND TECHNOLOGY LICENSE AGREEMENT (Exhibit 10.5)
The P65 tumor marker work on canines is outlined in (Exh. 10/6)
news on 5/9/2005 reported in an 8-K
Xpention Genetics Inc. appointed a scientist, Dr. Zbigniew Walaszek as the Company's Chief Scientific Officer and Chairman of the Scientific Advisory Committee.
Dr. Walaszek received his Ph.D. in Bio-Organic Chemistry at Silesia Technical University and received postgraduate training at Ohio State University. He currently holds the position of Scientist at AMC Cancer Research Center and is a member of the University of Colorado Cancer Center in Denver, Colorado. Dr. Walaszek recently received an appointment to the faculty of The University of Texas Health Science Center in San Antonio, Texas as Associate Professor in the Department of Pharmacology. Dr. Walaszek was a member of the team of researchers which discovered the relationship between P65 and the presence of cancerous tumors. The work performed by Dr. Walaszek and his colleagues led to the issuance of three patents, owned by The University of Texas MD Anderson Cancer Center.
5/11/05 filing 13D
it appears that the Regency Group liquidatd it's interests in the former shell. I do not know what the terms were.
the Reporting Entity acquired the securities in January 2005 in order to control the Company. The reporting entity distributed 13,650,000 (postforward split) shares in kind in a partial liquidation of its interest holders pro rata to their ownership. The Reporting Entity is no longer required to report since it no longer has any ownership.
XPNG: due diligence #2
sorry...can't relate all the details of my long conversation Friday morning at this time...have other priorities before the open tomorrow. i alluded to an email that Brian Cook from theregencygroup sent me, the 3 pager. Much of it's text is directly stated on the XPNG website.
This 3pager gives the business plan and the timelines quite nicely and is worth the read:
Xpention Genetics, Inc. (symbol: XPNG) is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods for both veterinary and human cancers. Xpention has licensed, exclusive rights to a specific genetic marker called the p65 that has highly specific correlation to numerous cancers.
Xpention has entered into a Patent and Technology License Agreement with The University of Texas M.D. Anderson Cancer Center which grants Xpention the exclusive right to patented technology for the detection of cancer based on a tumor marker known as p65 which has been demonstrated to have elevated levels in the blood of canine and human cancer conditions.
BACKGROUND
Human cancers
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Cancer is caused by both external factors (tobacco, chemicals, radiation, and infectious organisms) and internal factors (inherited mutations, hormones, immune conditions, and mutation that occur from metabolism). Causal factors may act together or in sequence to initiate or promote cancer development.
About 1,300,000 new cases of cancer were diagnosed in 2003. This year about 550,000 Americans are expected to die of cancer, more than 1,500 people a day. Cancer is now the number 1 leading cause of death in the U.S. exceeding even heart disease in 2004. In the U.S., 1 out of every 4 deaths is attributable to cancer.
The National Institutes of Health estimate overall costs for cancer in the year 2002 at $171.6 billion. $60.9 billion for direct medical costs (total of all health expenditures) and $15.5 billion for indirect morbidity costs (cost of lost productivity due to premature death). An estimated 250,000 new cases of breast cancer in women and 220,000 new cases of prostate cancer in men occurred in 2003.
Companion Animal Cancers
There are 65 million pet dogs and nearly 78 million pet cats in the United States, most of whom are considered part of the family. U.S. expenditure on veterinary care for pets in 2004 has grown over previous years and is estimated at $8.3 billion with an additional $7.9 billion in supplies and medicine (APPMA 2003/2004 National Pet Owner’s Survey). Companion animals are living longer and healthier lives, but are also experiencing a higher frequency of disease. Diagnosis of disease occurs more commonly in the late stages of life.
Cancer is the number one cause of natural death in senior dogs and cats and accounts for nearly 50% of deaths each year. One of the most common forms of canine cancer, lymphosarcoma, has an annual incidence of approximately 100,000 new cases. Dogs in fact experience approximately the same rate of cancer as humans do, although the prevalence is slightly lower with cats. It is notable however, that of the other common geriatric veterinary diseases (e.g. congestive heart failure, renal failure and diabetes mellitus), cancer is the most treatable. Treatments include surgery, radiation and chemotherapy. Treatment success is often a function of how progressed the cancer is at time of diagnosis.
Given the frequency of these diseases and the lengths to which pet owners will go to keep their animals healthy and happy into their senior years, the availability of a simple screening tool and monitoring method that would detect cancers would be extremely helpful for the future of veterinary medicine. This test could be used as part of a senior wellness evaluation, or as part of routine follow-up after detecting symptoms.
Diagnosis Methods
Current methods for diagnosis include costly imaging techniques and invasive procedures. Evaluation of the success of therapy is accomplished by using routine biochemistry and hematology testing, imaging and analysis of symptoms. Early detection and treatment would provide the best odds of attaining remission.
XPENTION SOLUTION
Xpention has the rights to a genetic marker in the blood called, P65. P65 is a promising marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission. Levels of p65 also appear to have a direct correlation to tumor mass/size. Initially, the Company will utilize its licensed technology to develop an immunological test for the detection of cancer in canines. The development stage is anticipated to last approximately six to eight months. Following development of the immunological test, the Company will seek to commercialize the test through licensing the test to third parties for sale and distribution.
Simultaneously, the Company will utilize its licensed technology to develop a molecular assay for detection of cancer in both humans and canines. The molecular test will be a more sensitive test and can initially be used both as a confirmation test as well as providing an ongoing measure of therapeutic success in canines and ultimately for cancer screening in humans. The duration of the development stage for the molecular assay is anticipated to be approximately twelve months. Upon successful development of the molecular assay, the Company will also seek to commercialize the molecular test; however, unlike the immunological test that will be licensed, all molecular testing will be conducted by the Company in a CLIA-certified laboratory thereby avoiding the requirement for FDA approval.
INITIAL STUDY OF P65
P65 is a promising marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission. Levels of p65 also appear to have a direct correlation to tumor mass.
In an initial study performed, 67 dogs with lymphosarcoma and 14 normal dogs were evaluated for p65 levels with the following findings:
Sensitivity: 0.94
Specificity: 0.70
Predictive Value: 0.83
(elevated p65 & presence of cancer)
P65 THERAPEUTIC VACCINE
Following development of the molecular assay, the company will pursue development of therapeutic vaccines utilizing RNAi (interference RNA) technology. Any changes in the genetic dynamic of P65 will steer cells toward abnormal growth resulting in tumor development. The hallmark of P65 alteration is a pronounced increase in the level of gene expression. Other oncogenes such as ERB2 are found to be elevated primarily in breast cancer. It has been shown that once the level of ERB2 goes back to normal, cancer growth slows down or disappears.
Xpention’s approach to vaccine development relies on the use of RNAi technology. RNAi is a novel technique capable of manipulating the level of a target gene by “interfering” with its genetic expression. This technology has been successfully applied to a variety of genetic targets including cancer and viral genes. Xpention is developing adenoviral vector based delivery systems that contain genetic elements unique to P65 sequences. By interfering with the genetic machine responsible for the altered levels of P65 in cancer cells, Xpention aims to revert or slow down the neoplastic process. An “in vitro” and mouse model for P65 related cancer growth has already been developed. The company will also employ the “Integrated technology platform system” (ITPS) to determine the efficacy of adenovirus vector RNAi based vaccine (AVVRNAi). Levels of p65 are measured before and at different time points after AVVRNAi injections in mice. Different dosages of vaccine will be used to determine the proper concentrations based on the highest levels of P65 gene inhibition. ITPS will greatly expedite the preclinical stage of the P65 vaccine development allowing a faster and more efficient start of human clinical studies.
KEY RELATIONSHIPS
AMC CANCER RESEARCH CENTER
Since 1904 AMC Cancer Research Center has dedicated itself to the relief of human suffering, and the treatment of major diseases. AMC has a long tradition of service to the entire U.S. This organization was originally founded as the JCRS (Jewish Consumptives Relief Society), a charitable hospital and research center that treated patients with tuberculosis (TB). In 1989 AMC began focusing entirely on research and ways to control cancer, to help patients live longer, and most importantly to PREVENT cancer before it ever starts. AMC operates a CLIA certified lab in the Denver area.
UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER
The University of Texas M. D. Anderson Cancer Center is located in Houston on the sprawling campus of the Texas Medical Center. It is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. M. D. Anderson ranks among the nation's top two cancer hospitals in U.S. News & World Reports "America's Best Hospitals" survey since its inception 13 years ago. Since 1944, more than 600,000 patients have turned to M. D. Anderson for cancer care in the form of surgery, chemotherapy, radiation therapy, immunotherapy or combinations of these and other treatments. More than 11,000 patients participated in clinical research exploring novel therapies and diagnostic tests in 2003, the largest such program in the nation.
more XPNG IR connections
current company IR
Barry Reagh@hotmail.com
888 359-9505
call to request snailmail investor's package
www.theregencygroup.net (haven't got this link to work)
Brian Cook, Aaron Lamkin, Scott Gelband(sp?) 303 771-7300
I believe that theregency group set up Barry to take calls on XPNG that were based on the email that went out this past week.
I've never spoken with Murray Fleming, but will try tomorrow
the OTC Special Situations Report lists 888-458-1945 as the # to call for more information and this is also the number for Murray Fleming at Catalyst IR according to the ibox. The 5/3 PR re. the appointment of Dr. Walaszek gives Mr. Fleming's # as 888-359-9505, so I don't know if both #s are active or not. I think our moderator gave Regency's # as Mr. Fleming's...whatever
am transcribing my notes from Friday's conversation with Aaron to follow soon.
one caveat from a cursory scan of the OTC SS report: at the top of page 6 is states... Short-circuiting cancer cells: XPNG is developing an anti-cancer vaccine that could
“interfere” with the cellular mechanism responsible for cells becoming cancerous.
From MY conversation...this is the holy grail that XPNG is hoping for, the development of an anti-cancer vaccine. It may be a stretch to state that they are developing the vaccine at THIS point in time.
Link to the XPNG "OTC Special Situations Report"
http://204.9.191.148/XPNG/XPNG.pdf
the reports disclaimer:
IMPORTANT DISCLAIMER: This paid advertising issue of OTC
Growth Stock Watch (hereafter “OTC”) does not purport to provide
an analysis of any company’s financial position and is not
in any way to be construed as an offer or solicitation to buy or
sell any security. OTC is a paid advertiser. Xpention Genetics
Inc. (hereafter “XPNG”) is the featured company. C.I. Marketing,
L.L.C. (hereafter “CIM”) managed the publishing and distribution
of this publication. CIM is a financial communications company
that disseminates information via paid advertisements. Although
the information contained in this advertisement is believed to be
reliable, CIM, OTC and its editors make no warranties as to the
accuracy of the description of any of the content herein and
accept no liability for how readers may choose to utilize it. The
information contained herein is being republished from publicly
disseminated information issued by third parties regarding
XPNG and are presumed to be reliable, but neither CIM nor
OTC or their editors accept any responsibility for the accuracy
of such information. Neither OTC, CIM nor any of their principals,
officers, directors, partners, agents, or affiliates are not, nor do
we represent ourselves to be brokers, or dealers in securities.
Readers should independently verify all statements made in
this advertisement. CIM, as well as various affiliated companies
and vendors have received and managed a total production
budget of five hundred sixty thousand dollars received from
0711005BC, Ltd. (LTD) for this advertising effort and will retain,
over and above the cost of production and publication, any
amounts that remain as additional compensation for production
services relating to the advertising and publishing efforts.
Please make special note that LTD owns shares of XPNG and
reserves the right to sell any or all of its shares in any company
profiled at any time, be that before the date of a profile, during
the date of a profile, or at anytime after the date of a profile, as
has been the practice of XPNG on many occasions. OTC expects
to receive new subscriber revenue, the amount of which is unknown
at this time
As regard Geoffrey Eiten and his affiliated companies: XPNG is not a profiled company in the OTC Growth Stock Watch as the first email (and the link to the Special Situations Report implies). Eiten had nothing to do with the Report except to sign off on it's content for publication, though they may have made some "target-like" statements as evidenced by the text.
OTC Special Situations IS designed to generate subscriptions. Although XPNG may one day be a client of the OTC FN they are not clients right now.
Quickly now, before i can no longer edit:
XPNG had IR:
attached to a previous press release...
Murray Fleming
Catalyst Investor Relations 888 458-1945
Ir@xpention.com
don't know his current status
......
a relationship with TheRegencyGroup
whose emails I posted
.......
an email promo
sent out by CCarver@InvestorsObserver.com
Murray Fleming
Catalyst Investor Relations 888 458-1945
Ir@xpention.com
....
a suspected...and now existing OTC Special Situations Report like that of LLLI that is heading out the snail mail system produced by CIM? no idea yet who they are or their relationship to insiders/ big holders etc
thx for all kind replies
could not get stockcharts links to give me less than daily...
here is a 10day bigchart 15' chart:
Seems like many are looking for the next rocket ship/reverse merger/ Eiten-linked/ LLLI type runner.
This will lead to inevitable disappointment imo.
The reason I spent so much time Friday morning speaking with those involved in the "rollup" was to diagnose the similarities and differences with LLLI.
As I stated in my previous post, not only was HIGGS from the Turks & Caicos involved in LLLI's bridge financing, they also spent over $1 million on the OTC Special Situations promoo. It is my belief that they, or their proxies, were also on the bid for much of the run from the 1.90 area up above 3.00.
At a certain point in time a runner takes on a life of its own and no longer needs a big money player's bid support. They say it takes $ to make $, and Higgs et. al. did a masterful job. They may still be doing it for all I know.
You are all aware of the bell curve and how you want to be in at the beginning of the markup phase and scaling out as distribution begins to overtake accumulation.
I feel pretty certain that XPNG is just starting up that curve, BUT it will take some serious bid support sustained over time, and it is not clear to me how serious the promotional interested parties are at this point. If, in fact, there is an OTC Special Situations report being prepared for mailing, well.... :)
The disclaimer from the email promo states that: "Agile Investments Ltd received compensation for this newsletter service. The compensation is $80,000 from a non-affiliated third party." The email i received was sent from CCarver@InvestorsObserver.com. I do not know what InvestorsObserver.com is...Will try to check them out later. here is a link...http://www.investorsobserver.com/index.asp
Maybe one of you can find the connection between this site and the promo that was emailed.
As previously mentioned I have not had a chance to review the patent documents or any of the research articles on the p65 gene marker. The email promo did cover the main points of the story effectively and succinctly imo.
I will hopefully be able to review my notes from Friday morning's calls for a post on Monday evening that will outline the company's business plan.
Have also not been able to analyze who the significant players are as represented in the level II box. I did discuss this with Aaron from the RegencyGroup. There were a couple of unfamiliar MMIDs on Friday morning, but I was too busy to really watch their behavior pattern.
[One thing I DID learn is that Schwab market maker activity is now being handled by UBSS! If you see SCHB now...it is not Schwab...I can hardly believe this. More later...this was reported to me, but I have not confirmed it independently.]
ok...more coming soon
Hi all: XPNG due diligence #1
After receiving an email about XPNG from CCarver@InvestorsObserver.com I made a few phone calls:
I spoke on Friday with Geoff Eiten from OTC FN, Aaron from the Regency Group, and Barry Reagh, who is answering the IR phones at 888 359-9505. A call to him will get you a snail mail IR package sent your way.
Is very late and I have much to post but here is a start:
1) The 1.50 print on the first day of trading was rather spurious from a charting perspective. Someone got fleeced on a market order of 1000 shares when it opened. Stock was really opened at 1.00.
2) Here is the email with some links I got from Brian:
Greetings Mike,
Genetic Diagnostics Recommended by Forbes. http://www.forbes.com/free_forbes/2005/0606/106.html
I wanted to inform you that Xpention Genetics Inc. has now gone public. Xpention is trading under the symbol (OTC BB: XPNG) and the company web address is www.Xpention.com. Xpention Genetics Inc. has entered into a Patent and Technology License Agreement with the world-renowned University of Texas M.D. Anderson Cancer Center. The agreement grants Xpention the exclusive right to patented technology for the detection of cancer based on a tumor marker known as P65, which has demonstrated to have elevated levels in the blood of canine and human cancer conditions. The P65 gene has been proven to have specific correlation to numerous cancer types including breast and prostate cancer in mammals. Please read the company 3 pager that is attached and do www.google.com searches on the, "P65 cancer gene". XPNG's exclusive commercial rights to the P65 has astronomical profit potential since the gene has proven to detect tumors before they begin!
It is also very important to understand how the company plans to go to market quickly with their non-invasive and inexpensive cancer diagnostic tests. Immediately after final development, the company plans to sell its cancer diagnostic tests in the multi-billion dollar Veterinary industry, specifically catering to pet owners. By also operating in a CLIA certified lab, Xpention Inc. can test human blood for cancer without a lengthy FDA approval process. The company not only can produce highly accurate, earlier detecting, inexpensive cancer tests, Xpention is also currently developing a genetic vaccine for breast and prostate cancer, which blocks the P65 gene from ever increasing in expression. Xpention Genetics Inc. potentially holds a key to effectively blocking breast and prostate cancer before it starts! Please contact me with any questions you may have.
University of Texas M.D. Anderson Cancer Center Press Release with XPNG http://biz.yahoo.com/iw/050427/085447.html
Patents available for viewing at http://www.xpention.com/patents.html
Best Regards,
Brian Cook
bc@theregencygroup.net
3) Here is a one pager that Barry from IR sent me
XPENTION GENETICS INC OTCBB: XPNG
CONIFER, CO
www.xpention.com
SHARES OUTSTANDING: 56,842,500
RESTRICTED / IN TREASURY: 27,950,000
PUBLIC FLOAT: 28,892,500
YEARS PUBLIC: APRIL 12TH, 2005 OPENED UP AT $1.50 / SHARE
FINANCING / CAPITAL: NO DATA AVALIABLE YET
MANAGEMENT: MR. DAVID KITTRELL, CHIEF EXECUTIVE OFFICER.
PRESS RELEASES
MAY 3, 2005, CHIEF EXECUTIVE OFFICER, DAVID KTTRELL, APPROINTED WORLD CLASS SCIENTIST, DR. ZBIGNIEW AS THE COMPANY’S CHIEF SCIENTIFIC OFFICER AND CHAIRMAN OF THE SCIENTIFIC ADVISORY COMMITTEE. DR. WALASZEK WAS A MEMBER OF THE TEAM OF RESEARCHERS WHICH DISCOVERED THE RELATIONSHIP BETWEEN p.65 AND THE PRESENCE OF CANCEROUS TUMORS.
MISSION
XPENTION GENETICS, INC IS A BIOTECHNOLOGY COMPANY THAT WAS FORMED TO DEVELOP BOTH IMMUNOLOGICAL AND MOLECULAR TESTS FOR CANCER DETECTION IN ANIMALS AND HUMANS AS WELL AS THERAPUTIC VACCINES AND OTHER TREATMENT METHODS FOR COMPANION ANIMAL CANCERS. XPENTION HAS LICENSED EXCLUSIVE RIGHTS TO A SPECIFIC GENETIC MARKER CALLED THE p65 THAT HAS A HIGHLY SPECIFIC CORRELATION TO NUMEROUS CANCERS.
OVERVIEW
XPENTION HAS THE RIGHTS TO A GENETIC MARKER IN THE BLOOD CALLED p65. P65 IS A PROMISING MARKER FOR THE EARLY DETECTION OF MALIGNANT TUMOR FORMATION AND A USEFUL TOOL FOR MONITORING THERAPY AND REMISSION. LEVELS OF p65 ALSO APPEAR TO HAVE A DIRECT CORRELATION TO TUMOR MASS/SIZE. INITIALLY, THE COMPANY WILL UTILIZE ITS LICENSED TECHNOLOGY TO DEVELOP AN IMMUNOLOGICAL TEST FOR THE DETECTION OF CANCER IN CANINES. THE DEVELOPMENT STAGE IS ANTICIPATED TO LAST APPROXIMATELY SIX TO EIGHT MONTHS. FOLLOWING DEVELOPMENT OF THE IMMUNOLOGICAL TEST, THE COMPANY WILL SEEK TO COMMERCIALIZE THE TEST THROUGH LICENSING THE TEST TO THIRD PARTIES FOR SALE AND DISTRIBUTION.
KEY POINTS
-SIGNED A LICENSING AGREEMENT WITH THE UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER, FOR THE USE OF THE p65 GENETIC MARKER.
-p65 WAS CO-DISCOVERED BY THOMAS SLAGA, PHD, WHOSE RESEARCH HAS DEMONSTRATED A DIRECT CORRELATION BETWEEN THE p65 MARKER AND THE FORMATION OF CANCEROUS TUMORS-RESEARCH HAS BEEN PATENTED AND OWNED BY THE UNIVERSITY OF TEXAS.
4) I spent over an hour on the phone with Aaron from the RegencyGroup and will report on my conversation with him later in the weekend
5) I was unable to find out who is behind the promotion (except that it is thought to be shareholders, not a distinterested third party). $80K was spent on the email promo...It does mention the OTC Growth Stock Watch with it's recommendation at 1.16 for a target of 9.20.
6) They have been offered financing and are trying to make a decision in that regard. I urged Regency who is providing the company with advice to be sure that warrant kickers are done at a premium and not discount to current share price levels. Regency is well aware of potential pitfalls from "more odious" kinds of financing. It won't be a PIPE
7) Current business plan is to get the veterinary piece going and it will take about 1-1.5 million to do the job over the next 8 or so months.
8) The only 2 employees currently are Mr. Kittrel and one of the patent holders, the new Chief Scientific Officer Dr. Zbigniew Walaszek.
9) Mr. Eiten clearly stated that XPNG was not a candidate for the Growth Stock Watch because of it's early stage of development. He stated that it would be an "OTC Special Situations" report. Although I have not confirmed the implication of this statement, I believe this means that they have, or will soon be publishing a snail mail type PR like the one that came out for LLLI. Eiten's group does not do the due diligence to create these promos. They publish them in order to build a subscription base. He told me that they expected something in the range of $30,000 in subscriptions from the LLI mailer. He did not know who was producing the PRs for XPNG and referred me to the RegencyGroup.
In the case of LLLI, Higgs Investment Group, who put up bridge financing of $1.5 million to complete the reverse merger from the shell, also spent $1.3 million to do the nice glossy promo.
(Their shares from the pp were Reg S and I saw no registration statement, so if they were on the up& up they were supporting the stock's climb by buying shares and probably selling after the momentum got going to recoup their promotional costs.) btw, they have 3 million warrants exercizeable at 1.25 for the first 12 months. (If they were to exercise they would have a nearly 10% stake in the company and would have to file a 13D which hasn't happened yet, so they probably have not yet exercised)
10) In my opinion this story is just beginning to unfold. FD: I am long at 1.27 with more than a starter but less than a full position.
Anyone wanting to followup on some of the links is more than welcome. I am very busy with a card tourney (duplicate bridge) all weekend and will not do more than recount the long conversation I had in my next post.
SUPG added 5.06
QUIK making up it's mind for the b.o.
MCX also a FANTASTIC scalping vehicle: check the price moves as the short term oscillator does it's thing....is nearing overbought right now...will watch for next low point in the stochastic
QUIK looks like cup w. handle breakout: added this morning